{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-063167","form_type":"8-K","ticker":null,"cik":"0001463361","company_name":"Unity Biotechnology, Inc.","filed_at":"2025-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.371613+00:00","generated_at":"2026-05-22T17:05:17.992613+00:00","sec_items":["2.05","8.01","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Unity Biotech lays off all employees, explores strategic alternatives after Phase 2b miss","bullets":["Company reducing entire workforce; expects $3.7M in severance and related cash costs; completion by May 15, 2025.","CEO Anirvan Ghosh, CFO Lynne Sullivan, and Chief Legal Officer Alexander Nguyen will terminate employment May 15, transition to advisory consulting roles.","Phase 2b ASPIRE study of UBX1325 in DME showed non-inferiority to aflibercept at week 36 but missed primary endpoint at average of weeks 20 and 24.","Strategic alternatives include sale, license, monetization, merger, or wind-down of the company; no assurance of any transaction.","Cash and equivalents $16.9M as of March 31, 2025; company reducing operational cash burn."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-063167","json":"https://secwatch.observer/filing/0000950170-25-063167.json","markdown":"https://secwatch.observer/filing/0000950170-25-063167.md","text":"https://secwatch.observer/filing/0000950170-25-063167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/ubx-20250502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T17:05:17.992613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f5404830d","claim":"Anirvan Ghosh departed as Chief Executive Officer at Unity Biotechnology, Inc..","evidence_excerpt":"each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated employment"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b0f7867614","claim":"Lynne Sullivan departed as Chief Financial Officer and Head of Corporate Development at Unity Biotechnology, Inc..","evidence_excerpt":"each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated employment"},{"label":"Role","value":"Chief Financial Officer and Head of Corporate Development"}],"fact_type":"executive_change"},{"claim_id":"f0c1857912","claim":"Alexander Nguyen departed as Chief Legal Officer and Head of Operations at Unity Biotechnology, Inc..","evidence_excerpt":"each of Anirvan Ghosh, Lynne Sullivan, and Alexander Nguyen, the Company’s Chief Executive Officer, Chief Financial Officer and Head of Corporate Development, and Chief Legal Officer and Head of Operations, respectively, will terminate employment with the Company, effective May 15, 2025","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated employment"},{"label":"Role","value":"Chief Legal Officer and Head of Operations"}],"fact_type":"executive_change"},{"claim_id":"760784acec879ec40412a838f55f43afdf189e29","claim":"Unity Biotechnology, Inc. announced a restructuring with charges of approximately $3.7 million (a reduction in force affecting all of its employees).","evidence_excerpt":"The Company estimates that it will incur aggregate cash expenses of approximately $3.7 million in connection with the reduction in force, including severance, benefits, and related termination costs, which includes fees to be paid under consulting agreements.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1463361/000095017025063167/0000950170-25-063167-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.7 million"},{"label":"Headcount","value":"a reduction in force affecting all of its employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}